東華大學圖書館 |

Engineering a Robust and Scalable Platforn for the Production of IEILC1-Like Nk Cells, a Novel Solid Tumor Immunothereapeutic Modality.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Engineering a Robust and Scalable Platforn for the Production of IEILC1-Like Nk Cells, a Novel Solid Tumor Immunothereapeutic Modality./
作者:	Horowitz, Nina Beryl.
面頁冊數:	1 online resource (119 pages)
附註:	Source: Dissertations Abstracts International, Volume: 84-05, Section: B.
Contained By:	Dissertations Abstracts International84-05B.
標題:	Patients. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29756352click for full text (PQDT)
ISBN:	9798357513052

Engineering a Robust and Scalable Platforn for the Production of IEILC1-Like Nk Cells, a Novel Solid Tumor Immunothereapeutic Modality.
Horowitz, Nina Beryl.

Engineering a Robust and Scalable Platforn for the Production of IEILC1-Like Nk Cells, a Novel Solid Tumor Immunothereapeutic Modality. - 1 online resource (119 pages)

Source: Dissertations Abstracts International, Volume: 84-05, Section: B.

Thesis (Ph.D.)--Stanford University, 2022.

Includes bibliographical references

While surgery, radiation, and chemotherapy have been the gold standards of cancer treatment for decades, they are severely limited in certain aspects -- not all tumors are operable, and chemotherapy and radiotherapy can damage healthy tissues as well as the cancer cells. Targeted therapy and immunotherapy were hailed as solutions to this, but they also have drawbacks of their own. The first is that they can be extremely expensive, which leads to financial toxicity, and the second is that they can sometimes cause cytotoxicity to healthy tissues or even occasionally kill the patients they are meant to treat. Natural killer (NK) cell-based therapies solve both issues as they exhibit an optimal safety profile and can be given off-the-shelf to lower the cost of production, but their success has been mostly restricted to liquid tumors.Solid tumors account for 90% of all cancer diagnoses and are significantly more difficult to treat due to a variety of factors such as tumor heterogeneity, the immunosuppressive tumor microenvironment (TME), and poor immune cell trafficking. Here, I present our work designing NK cells with optimized functionalities for solid tumor indications. We have previously identified a novel population of NK cells within head and neck squamous cell carcinoma (SCC) patients that maintain an activated and highly proliferative phenotype within the TME and resemble intraepithelial group 1 innate lymphoid cells (ieILC1s) due to their expression of CD49a and CD103. In earlier work, we were able to induce moderate levels of CD49a and CD103 expression on peripheral blood NK cells through injection of the NK cells into subcutaneous tumors or co-culture with live tumor cells -- but these cells were not thoroughly studied in vitro or in vitro, and this functional evaluation is critical for designing solid tumor therapeutics.We designed cell culture systems that can reliably differentiate peripheral blood NK cells into highly pure, clinically relevant doses of ieILC1-like NK cells. This platform design involved comparing media conditions, cytokine exposure, feeder cell ratios, seeding density, and many other variables. We then assessed the ability of these ieILC1-like NK cells to kill target cells, produce inflammatory cytokines, interact with tumor-targeting antibodies and chimeric antigen receptors, and infiltrate solid tumors. Our results show that ieILC1-like NK cells exhibit high cytotoxicity, high production of cytokines, and tumor infiltration rates up to ten times higher than other NK cell products that are currently being tested in the clinic. This cytotoxicity can be enhanced by using antibodies or chimeric antigen receptors in manners similar to conventional NK cells. Furthermore, we established the role of the surface integrin CD103 as a critical molecular regulator of tumor invasion by NK cells. This work represents an important step forward in the design of affordable and accessible cell therapeutics for solid tumors.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023

Mode of access: World Wide Web

ISBN: 9798357513052Subjects--Topical Terms:

1961957
Patients.
Index Terms--Genre/Form:

542853
Electronic books.

Engineering a Robust and Scalable Platforn for the Production of IEILC1-Like Nk Cells, a Novel Solid Tumor Immunothereapeutic Modality.
LDR:04358nmm a2200361K 4500 001 2359866
005 20230917195309.5
006 m o d
007 cr mn ---uuuuu
008 241011s2022 xx obm 000 0 eng d
020 $a 9798357513052
035 $a (MiAaPQ)AAI29756352
035 $a (MiAaPQ)STANFORDbn410yt0588
035 $a AAI29756352
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Horowitz, Nina Beryl. $3 3700482
245 1 0 $a Engineering a Robust and Scalable Platforn for the Production of IEILC1-Like Nk Cells, a Novel Solid Tumor Immunothereapeutic Modality.
264 0 $c 2022
300 $a 1 online resource (119 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 84-05, Section: B.
500 $a Advisor: Barron, Annelise E. ; Engleman, Edgar G. ; Sunwoo, John.
502 $a Thesis (Ph.D.)--Stanford University, 2022.
504 $a Includes bibliographical references
520 $a While surgery, radiation, and chemotherapy have been the gold standards of cancer treatment for decades, they are severely limited in certain aspects -- not all tumors are operable, and chemotherapy and radiotherapy can damage healthy tissues as well as the cancer cells. Targeted therapy and immunotherapy were hailed as solutions to this, but they also have drawbacks of their own. The first is that they can be extremely expensive, which leads to financial toxicity, and the second is that they can sometimes cause cytotoxicity to healthy tissues or even occasionally kill the patients they are meant to treat. Natural killer (NK) cell-based therapies solve both issues as they exhibit an optimal safety profile and can be given off-the-shelf to lower the cost of production, but their success has been mostly restricted to liquid tumors.Solid tumors account for 90% of all cancer diagnoses and are significantly more difficult to treat due to a variety of factors such as tumor heterogeneity, the immunosuppressive tumor microenvironment (TME), and poor immune cell trafficking. Here, I present our work designing NK cells with optimized functionalities for solid tumor indications. We have previously identified a novel population of NK cells within head and neck squamous cell carcinoma (SCC) patients that maintain an activated and highly proliferative phenotype within the TME and resemble intraepithelial group 1 innate lymphoid cells (ieILC1s) due to their expression of CD49a and CD103. In earlier work, we were able to induce moderate levels of CD49a and CD103 expression on peripheral blood NK cells through injection of the NK cells into subcutaneous tumors or co-culture with live tumor cells -- but these cells were not thoroughly studied in vitro or in vitro, and this functional evaluation is critical for designing solid tumor therapeutics.We designed cell culture systems that can reliably differentiate peripheral blood NK cells into highly pure, clinically relevant doses of ieILC1-like NK cells. This platform design involved comparing media conditions, cytokine exposure, feeder cell ratios, seeding density, and many other variables. We then assessed the ability of these ieILC1-like NK cells to kill target cells, produce inflammatory cytokines, interact with tumor-targeting antibodies and chimeric antigen receptors, and infiltrate solid tumors. Our results show that ieILC1-like NK cells exhibit high cytotoxicity, high production of cytokines, and tumor infiltration rates up to ten times higher than other NK cell products that are currently being tested in the clinic. This cytotoxicity can be enhanced by using antibodies or chimeric antigen receptors in manners similar to conventional NK cells. Furthermore, we established the role of the surface integrin CD103 as a critical molecular regulator of tumor invasion by NK cells. This work represents an important step forward in the design of affordable and accessible cell therapeutics for solid tumors.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2023
538 $a Mode of access: World Wide Web
650 4 $a Patients. $3 1961957
650 4 $a Metastasis. $3 818532
650 4 $a Antibodies. $3 709277
650 4 $a Immunotherapy. $3 597370
650 4 $a Cytotoxicity. $3 3682273
650 4 $a Cancer therapies. $3 3557730
650 4 $a Immune system. $3 689864
650 4 $a Cytokines. $3 687114
650 4 $a Response rates. $3 3564350
650 4 $a Medical research. $2 bicssc $3 1556686
650 4 $a Clinical trials. $3 724498
650 4 $a Lymphocytes. $3 895384
650 4 $a Antigens. $3 700737
650 4 $a Tumors. $3 893964
650 4 $a Lymphoma. $3 802273
650 4 $a Immunocompetence. $3 3700438
650 4 $a Protein expression. $3 3554057
650 4 $a Cellular biology. $3 3172791
650 4 $a Immunology. $3 611031
650 4 $a Oncology. $3 751006
650 4 $a Pharmaceutical sciences. $3 3173021
655 7 $a Electronic books. $2 lcsh $3 542853
690 $a 0379
690 $a 0982
690 $a 0992
690 $a 0572
710 2 $a ProQuest Information and Learning Co. $3 783688
710 2 $a Stanford University. $3 754827
773 0 $t Dissertations Abstracts International $g 84-05B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29756352 $z click for full text (PQDT)